-
Notable Insider Buys of the Past Week: Foot Locker, Icahn Enterprises, Kraft Heinz And More
Saturday, December 5, 2020 - 2:43pm | 978Read More...Insider buying can be an encouraging signal for potential investors when markets face uncertainty. This past week, some insiders added to their stakes in REITs, a specialty retailer and a packaged foods giant. Some insiders were making return trips to the buy window to increase their stakes....
-
Amicus Therapeutics Gains 3% On Favorable EU Medicines Recommendation
Friday, April 1, 2016 - 2:37pm | 392Read More...Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD), a bio-pharmaceutical company that focuses on the treatment of rare and orphan diseases, were trading higher by 3 percent Friday afternoon. Amicus Therapeutics announced earlier in the day that the European Committee for Medicinal Products for...
-
BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)
Wednesday, March 12, 2014 - 10:01am | 808Read More...Short interest in most of the leading biotech and emerging pharmaceutical companies declined between the February 14 and February 28 settlement dates. But Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) bucked that trend. Short interest in Gilead...
-
Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)
Thursday, February 27, 2014 - 1:26pm | 788Read More...Among the leading biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB) and BioMarin Pharmaceutical (NASDAQ: BMRN) saw the largest percentage increases in short interest between the January 31 and February 15 settlement dates. Alexion Pharmaceuticals,...
-
BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)
Thursday, February 13, 2014 - 11:18am | 777Read More...Among the leading biotech and emerging pharmaceutical companies, Incyte (NASDAQ: INCY) and Pharmacyclics (NASDAQ: PCYC) saw the largest percentage declines in short interest between the January 15 and January 31 settlement dates. Short sellers shied away from Alexion Pharmaceuticals, Amgen, Biogen...
-
New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)
Wednesday, January 29, 2014 - 12:44pm | 807Read More...Among the leading biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) saw the most significant upswings between the December 31 and January 15 settlement dates. Gilead Sciences, Pharmacyclics and Regeneron...
-
Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, CELG, DNDN)
Saturday, January 11, 2014 - 12:46pm | 778Read More...The number of shares sold short in leading biotech and emerging pharmaceutical companies mostly declined between the December 13 and December 31 settlement dates. BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) led that trend. Short sellers also shied...
-
Gilead Sciences Leads In Rising Short Interest Among Biotechs
Tuesday, November 12, 2013 - 5:41pm | 1296Read More...Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), BioMarin Pharmaceutical (NASDAQ: BMRN) and Gilead Sciences (NASDAQ: GILD) grew by the largest percentages in late October. Biogen Idec (NASDAQ: BIIB), Illumina...
-
Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)
Friday, October 25, 2013 - 3:36pm | 924Read More...Among leading biotech and emerging pharmaceutical companies, short sellers retreated from Biogen Idec (NASDAQ: BIIB) by the largest percentage in early October. Amgen (NASDAQ: AMGN), Illumina (NASDAQ: ILMN), Regeneron Pharmaceuticals (NASDAQ: REGN) and Seattle Genetics (NASDAQ: SGEN) saw short...
-
BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)
Wednesday, September 25, 2013 - 12:52pm | 897Read More...Among leading biotech and emerging pharmaceutical companies, short sellers moved on BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Regeneron Pharmaceuticals (NASDAQ: REGN) the most between the August 30 and September 13 settlement dates. The number of shares sold short in...
-
J.P. Morgan Maintains Neutral on Amicus Therapeutics (FOLD)
Tuesday, April 19, 2011 - 9:57am | 140Read More...J.P. Morgan is out with its report today on Amicus Therapeutics (NASDAQ: FOLD), maintaining Neutral. In a note to clients, J.P. Morgan writes, "We are Neutral on FOLD shares. Amicus' chaperone technology is a unique platform in biotech that could offer treatment for a wide range of diseases,...
